CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$999,994. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-06-07 | Koppikar Utpal Chief Financial Officer | Grant or award | +45,000 | 45,000 | ||
| 2018-06-07 | Koppikar Utpal Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2018-06-06 | Ciechanover Isaac E. Chief Executive Officer | Sale | −1,900 | $46.53 | $88K | 164,978 |
| 2018-06-06 | Ciechanover Isaac E. Chief Executive Officer | Sale | −1,500 | $47.69 | $72K | 163,478 |
| 2018-06-06 | Ciechanover Isaac E. Chief Executive Officer | Sale | −1,000 | $48.59 | $49K | 162,478 |
| 2018-06-05 | Ciechanover Isaac E. Chief Executive Officer | Sale | −3,200 | $49.51 | $158K | 168,078 |
| 2018-06-05 | Ciechanover Isaac E. Chief Executive Officer | Sale | −1,200 | $50.27 | $60K | 166,878 |
| 2018-05-22 | Ciechanover Isaac E. Chief Executive Officer | Sale | −4,400 | $50.88 | $224K | 171,278 |
| 2018-05-21 | Ciechanover Isaac E. Chief Executive Officer | Sale | −1,500 | $51.67 | $78K | 178,578 |
| 2018-05-21 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,000 | $52.83 | $106K | 176,578 |
| 2018-05-21 | Ciechanover Isaac E. Chief Executive Officer | Sale | −900 | $53.64 | $48K | 175,678 |
| 2018-05-18 | Clark Mitchall G. EVP & Chief R & QA Officer | Sale | −25,860 | $50.03 | $1.3M | 107,972 |
| 2018-05-16 | Clark Mitchall G. EVP & Chief R & QA Officer | Sale | −4,347 | $46.04 | $200K | 134,132 |
| 2018-05-16 | Clark Mitchall G. EVP & Chief R & QA Officer | Sale | −300 | $46.30 | $14K | 133,832 |
| 2018-05-16 | Gallagher Carol Giltner Director | Sale | −273 | $46.06 | $13K | 111,192 |
| 2018-05-15 | Porter Derrell SVP, Head of Global Commercial | Option exercise | +16,334 | $14.30 | $234K | 28,834 |
| 2018-05-15 | Porter Derrell SVP, Head of Global Commercial | Sale | −16,334 | $45.02 | $735K | 12,500 |
| 2018-05-15 | Porter Derrell SVP, Head of Global Commercial | Option exercise · Employee Stock Option (Right to Buy) | −16,334 | 113,666 | ||
| 2018-05-15 | Fust Matthew K Director | Option exercise | +534 | 20,354 | ||
| 2018-05-15 | Fust Matthew K Director | Option exercise · Restricted Stock Units | −534 | 0 |
Page 30 of 44 · 867 trades